Barclays PLC Analysts Give Roche Holding Ltd. (ROG) a CHF 295 Price Target
Roche Holding Ltd. (VTX:ROG) has been given a CHF 295 price target by investment analysts at Barclays PLC in a report released on Wednesday. The brokerage currently has a “buy” rating on the healthcare company’s stock.
A number of other brokerages also recently weighed in on ROG. Goldman Sachs Group, Inc. (The) set a CHF 335 target price on shares of Roche Holding and gave the stock a “buy” rating in a research note on Thursday, June 15th. J P Morgan Chase & Co reissued a “buy” rating on shares of Roche Holding in a research note on Wednesday, June 7th. Kepler Capital Markets set a CHF 231 target price on shares of Roche Holding and gave the stock a “neutral” rating in a research note on Tuesday, June 6th. Deutsche Bank AG set a CHF 273 target price on shares of Roche Holding and gave the stock a “buy” rating in a research note on Tuesday, June 6th. Finally, HSBC Holdings plc set a CHF 215 target price on shares of Roche Holding and gave the stock a “sell” rating in a research note on Tuesday, June 6th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of CHF 267.53.
Shares of Roche Holding (VTX ROG) traded up 0.25% during trading on Wednesday, reaching CHK 242.90. 1,350,799 shares of the company were exchanged. The stock’s 50-day moving average is CHK 243.45 and its 200-day moving average is CHK 252.48. The firm has a market cap of CHK 207.26 billion and a price-to-earnings ratio of 21.57. Roche Holding has a 52-week low of CHK 218.30 and a 52-week high of CHK 273.00.
ILLEGAL ACTIVITY WARNING: “Barclays PLC Analysts Give Roche Holding Ltd. (ROG) a CHF 295 Price Target” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/09/13/barclays-plc-analysts-give-roche-holding-ltd-rog-a-chf-295-price-target.html.
About Roche Holding
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.